Akeso Reported 2022 Annual Results ...Middle East

PR Newswire - News
Akeso Reported 2022 Annual Results
Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaled RMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales of RMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales...

Hence then, the article about akeso reported 2022 annual results was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Reported 2022 Annual Results )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News